Trending...
- Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
- UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
- Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"
SAN FRANCISCO - DelhiScan -- OKAVA Pharmaceuticals is a clinical-stage company developing medicines to enable dogs and cats to live longer, healthier lives. Today, the company announced that the first cat has been successfully dosed in MEOW-1 (ManagEment of OverWeight cats with OKV-119), a landmark clinical study evaluating OKV-119, an investigational, first-in-class, ultra-long-acting GLP-1 implant being developed specifically for weight management in cats. Beyond weight loss, the implications of this pet-tailored GLP-1 solution for diabetes, kidney disease, and healthy aging and longevity may be profound.
By improving cardiometabolic health through continuous delivery of a GLP-1 receptor agonist, OKV-119 has the potential to enhance quality of life, promote healthy aging, and become the most impactful life-extending therapy available for cats.
OKV-119 leverages the NanoPortal™ technology platform developed by Vivani Medical. The novel drug-delivery system is designed to provide smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. This "One-and-Done" hassle-free solution is designed to guarantee that cats remain adherent for up to six months with a single implant administered during a routine office visit.
MEOW-1 marks the first-ever GLP-1 weight-loss clinical trial in cats or dogs, a landmark moment for veterinary medicine. In human medicine, GLP-1 receptor agonists have revolutionized the management of obesity, diabetes, and cardiometabolic health, becoming one of the most important therapeutic breakthroughs of the 21st century. OKAVA is now working to bring this same transformational class of medicines to dogs and cats, with an ultra-long-acting solution specifically engineered for safe and effective use in companion animals.
More on Delhi Scan
"Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats," said Michael Klotsman, PhD, MBA, CEO of OKAVA. "But it's also one of the hardest to maintain. OKV-119 is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism — without requiring significant changes in feeding routines or disrupting the human–animal bond that often centers around food."
The MEOW-1 study is being conducted under an FDA-CVM Investigational New Animal Drug (INAD) application and will evaluate the safety, tolerability, and weight-loss efficacy of OKV-119 in overweight or obese client-owned cats. Results from the study will inform future clinical development and regulatory filings and are expected to guide the initiation of similar studies in dogs. As part of its commitment to responsible, transparent clinical research, OKAVA has listed the MEOW-1 study in the American Veterinary Medical Association (AVMA) Clinical Trials Registry.
About OKV-119
OKV-119 is a miniature, subdermal exenatide implant designed to address the growing prevalence of obesity, diabetes and kidney disease in cats. The product utilizes Vivani Medical's NanoPortal™ technology platform. The implant can be inserted under the skin during a routine veterinary visit and is designed to deliver a steady dose of medication for up to six months.
OKV-119 is being developed by OKAVA in partnership with Vivani Medical under an exclusive veterinary licensing and collaboration agreement.
More on Delhi Scan
About OKAVA Pharmaceuticals
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing breakthrough human technologies for the treatment of common diseases in household pets, the company has the potential to increase the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVA.com.
About Vivani Medical
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, see www.vivani.com.
For inquiries, contact:
Michael Klotsman
info@okava.com
415.818.1808
By improving cardiometabolic health through continuous delivery of a GLP-1 receptor agonist, OKV-119 has the potential to enhance quality of life, promote healthy aging, and become the most impactful life-extending therapy available for cats.
OKV-119 leverages the NanoPortal™ technology platform developed by Vivani Medical. The novel drug-delivery system is designed to provide smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. This "One-and-Done" hassle-free solution is designed to guarantee that cats remain adherent for up to six months with a single implant administered during a routine office visit.
MEOW-1 marks the first-ever GLP-1 weight-loss clinical trial in cats or dogs, a landmark moment for veterinary medicine. In human medicine, GLP-1 receptor agonists have revolutionized the management of obesity, diabetes, and cardiometabolic health, becoming one of the most important therapeutic breakthroughs of the 21st century. OKAVA is now working to bring this same transformational class of medicines to dogs and cats, with an ultra-long-acting solution specifically engineered for safe and effective use in companion animals.
More on Delhi Scan
- Kolbus Introduces the Next Step in Casemaking Efficiency
- Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
- Sounds of LA County: 27 Parks.108 Concerts. One County
- Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
- Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
"Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats," said Michael Klotsman, PhD, MBA, CEO of OKAVA. "But it's also one of the hardest to maintain. OKV-119 is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism — without requiring significant changes in feeding routines or disrupting the human–animal bond that often centers around food."
The MEOW-1 study is being conducted under an FDA-CVM Investigational New Animal Drug (INAD) application and will evaluate the safety, tolerability, and weight-loss efficacy of OKV-119 in overweight or obese client-owned cats. Results from the study will inform future clinical development and regulatory filings and are expected to guide the initiation of similar studies in dogs. As part of its commitment to responsible, transparent clinical research, OKAVA has listed the MEOW-1 study in the American Veterinary Medical Association (AVMA) Clinical Trials Registry.
About OKV-119
OKV-119 is a miniature, subdermal exenatide implant designed to address the growing prevalence of obesity, diabetes and kidney disease in cats. The product utilizes Vivani Medical's NanoPortal™ technology platform. The implant can be inserted under the skin during a routine veterinary visit and is designed to deliver a steady dose of medication for up to six months.
OKV-119 is being developed by OKAVA in partnership with Vivani Medical under an exclusive veterinary licensing and collaboration agreement.
More on Delhi Scan
- World Cup Crowds Are a Stress Test for America's Restrooms
- Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
- How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
- Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
- Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
About OKAVA Pharmaceuticals
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing breakthrough human technologies for the treatment of common diseases in household pets, the company has the potential to increase the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVA.com.
About Vivani Medical
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, see www.vivani.com.
For inquiries, contact:
Michael Klotsman
info@okava.com
415.818.1808
Source: OKAVA
0 Comments
Latest on Delhi Scan
- Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
- CCHR: DOJ Takedown Exposes Over $220 Million Defrauded in Behavioral Mental Health Fraud Schemes
- Lady Liberty Is Coming Home: Historic WWII A-26 Invader Begins Her Final Journey to the Tulsa Air & Space Museum
- The Lashe Announces Limited-Time Sale on Professional Premade Fan Lash Extension Trays
- PropAccount.com Adds Prediction Markets to Its Multi-Asset Prop Firm Platform
- Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"
- UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
- Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
- June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
- Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
- Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
- Make America French Again Launches National Campaign
- RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
- 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
- Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
- Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
- Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
- OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
- Dentists launch independent platform to help practices choose the right technology
- Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree